Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Biote (BTMD) Other financing activities (2021 - 2022)

Biote has reported Other financing activities over the past 2 years, most recently at -$4.3 million for Q4 2022.

Quarterly results put Other financing activities at -$4.3 million for Q4 2022, down 220.82% from a year ago — trailing twelve months through Dec 2022 was $4.0 million (up 2.41% YoY), and the annual figure for FY2022 was $4.0 million, up 2.41%.
Other financing activities for Q4 2022 was -$4.3 million at Biote, down from $6.8 million in the prior quarter.
Over the last five years, Other financing activities for BTMD hit a ceiling of $6.8 million in Q2 2022 and a floor of -$4.3 million in Q4 2022.